Gregory M Woods

List of Publications by Year
in descending order

107 papers	3,545 citations	185998 28 h-index	161609 54 g-index
116 all docs	116 docs citations	116 times ranked	3270 citing authors

#	Article	IF	Citations
1	Cathelicidin-3 Associated With Serum Extracellular Vesicles Enables Early Diagnosis of a Transmissible Cancer. Frontiers in Immunology, 2022, 13, 858423.	2.2	3
2	Expression of the Nonclassical MHC Class I, Saha-UD in the Transmissible Cancer Devil Facial Tumour Disease (DFTD). Pathogens, 2022, 11, 351.	1.2	0
3	Challenges of an Emerging Disease: The Evolving Approach to Diagnosing Devil Facial Tumour Disease. Pathogens, 2022, 11, 27.	1.2	1
4	Tasmanian devil CD28 and CTLA4 capture CD80 and CD86 from adjacent cells. Developmental and Comparative Immunology, 2021, 115, 103882.	1.0	7
5	Mesenchymal plasticity of devil facial tumour cells during in vivo vaccine and immunotherapy trials. Immunology and Cell Biology, 2021, 99, 711-723.	1.0	5
6	NLRC5 regulates expression of MHC-I and provides a target for anti-tumor immunity in transmissible cancers. Journal of Cancer Research and Clinical Oncology, 2021, 147, 1973-1991.	1.2	14
7	Extracellular vesicle proteomes of two transmissible cancers of Tasmanian devils reveal tenascin-C as a serum-based differential diagnostic biomarker. Cellular and Molecular Life Sciences, 2021, 78, 7537-7555.	2.4	6
8	Post-release immune responses of Tasmanian devils vaccinated with an experimental devil facial tumour disease vaccine. Wildlife Research, 2021, 48, 701-712.	0.7	7
9	Two of a kind: transmissible Schwann cell cancers in the endangered Tasmanian devil (Sarcophilus) Tj ETQq1 1 0.784314 rgBT /Overlock	2.4	28
10	Curse of the devil: molecular insights into the emergence of transmissible cancers in the Tasmanian devil (Sarcophilus harrisii). Cellular and Molecular Life Sciences, 2020, 77, 2507-2525.	2.4	12
11	A Devil of a Transmissible Cancer. Tropical Medicine and Infectious Disease, 2020, 5, 50.	0.9	8
12	A novel system to map protein interactions reveals evolutionarily conserved immune evasion pathways on transmissible cancers. Science Advances, 2020, 6, .	4.7	22
13	Evolution and lineage dynamics of a transmissible cancer in Tasmanian devils. PLoS Biology, 2020, 18, e3000926.	2.6	23
14	Evolution and lineage dynamics of a transmissible cancer in Tasmanian devils. , 2020, 18, e3000926.		0
15	Evolution and lineage dynamics of a transmissible cancer in Tasmanian devils. , 2020, 18, e3000926.		0
16	Evolution and lineage dynamics of a transmissible cancer in Tasmanian devils. , 2020, 18, e3000926.		0
17	Evolution and lineage dynamics of a transmissible cancer in Tasmanian devils. , 2020, 18, e3000926.		0
18	Targeting transmissible cancers in animals. Science, 2019, 365, 438-440.	6.0	9

#	Article	IF	Citations
19	Editorial: Wild Immunologyâ€"The Answers Are Out There. Frontiers in Immunology, 2019, 10, 126.	2.2	3
20	TNF May Negatively Regulate Phagocytosis of Devil Facial Tumour Disease Cells by Activated Macrophages. Immunological Investigations, 2019, 48, 691-703.	1.0	4
21	Tracing the rise of malignant cell lines: Distribution, epidemiology and evolutionary interactions of two transmissible cancers in Tasmanian devils. Evolutionary Applications, 2019, 12, 1772-1780.	1.5	37
22	The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. Cancer Cell, 2019, 35, 125-139.e9.	7.7	43
23	Gomesin peptides prevent proliferation and lead to the cell death of devil facial tumour disease cells. Cell Death Discovery, 2018, 4, 19.	2.0	15
24	The Origins and Vulnerabilities of Two Transmissible Cancers in Tasmanian Devils. Cancer Cell, 2018, 33, 607-619.e15.	7.7	88
25	Maternal exposure to particulate matter alters early post-natal lung function and immune cell development. Environmental Research, 2018, 164, 625-635.	3.7	13
26	Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells. Oncotarget, 2018, 9, 15895-15914.	0.8	13
27	Two Decades of the Impact of Tasmanian Devil Facial Tumor Disease. Integrative and Comparative Biology, 2018, 58, 1043-1054.	0.9	10
28	Immunization Strategies Producing a Humoral IgG Immune Response against Devil Facial Tumor Disease in the Majority of Tasmanian Devils Destined for Wild Release. Frontiers in Immunology, 2018, 9, 259.	2.2	37
29	Heat shock proteins expressed in the marsupial Tasmanian devil are potential antigenic candidates in a vaccine against devil facial tumour disease. PLoS ONE, 2018, 13, e0196469.	1.1	6
30	Inducible IFN-Î³ Expression for MHC-I Upregulation in Devil Facial Tumor Cells. Frontiers in Immunology, 2018, 9, 3117.	2.2	17
31	The newly-arisen Devil facial tumour disease 2 (DFT2) reveals a mechanism for the emergence of a contagious cancer. ELife, 2018, 7, .	2.8	47
32	Regression of devil facial tumour disease following immunotherapy in immunised Tasmanian devils. Scientific Reports, 2017, 7, 43827.	1.6	64
33	The absence of TNF permits myeloid Arginase 1 expression in experimental L. monocytogenes infection. Immunobiology, 2017, 222, 913-917.	0.8	13
34	The toll-like receptor ligands HiltonolÂ® (polyICLC) and imiquimod effectively activate antigen-specific immune responses in Tasmanian devils (Sarcophilus harrisii). Developmental and Comparative Immunology, 2017, 76, 352-360.	1.0	16
35	Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. Frontiers in Immunology, 2017, 8, 513.	2.2	19
36	PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-Î³ and Can Be Expressed in the Tumor Microenvironment. Frontiers in Immunology, 2016, 7, 581.	2.2	41

#	Article	IF	Citations
37	Fucoidan Suppresses the Growth of Human Acute Promyelocytic Leukemia Cells In Vitro and In Vivo. Journal of Cellular Physiology, 2016, 231, 688-697.	2.0	37
38	Demonstration of immune responses against devil facial tumour disease in wild Tasmanian devils. Biology Letters, 2016, 12, 20160553.	1.0	87
39	Mitogenâ€activated Tasmanian devil blood mononuclear cells kill devil facial tumour disease cells. Immunology and Cell Biology, 2016, 94, 673-679.	1.0	19
40	Discovery of Biomarkers for Tasmanian Devil Cancer (DFTD) by Metabolic Profiling of Serum. Journal of Proteome Research, 2016, 15, 3827-3840.	1.8	13
41	Devil Facial Tumor Disease. Veterinary Pathology, 2016, 53, 726-736.	0.8	22
42	A second transmissible cancer in Tasmanian devils. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 374-379.	3.3	192
43	The Immunomodulatory Small Molecule Imiquimod Induces Apoptosis in Devil Facial Tumour Cell Lines. PLoS ONE, 2016, 11, e0168068.	1.1	12
44	Fucoidan enhances the therapeutic potential of arsenic trioxide and all-trans retinoic acid in acute promyelocytic leukemia, <i>in vitro</i> and <i>in vivo</i>. Oncotarget, 2016, 7, 46028-46041.	0.8	20
45	Fucoidan and Cancer: A Multifunctional Molecule with Anti-Tumor Potential. Marine Drugs, 2015, 13, 2327-2346.	2.2	245
46	Toll-like receptor signaling is functional in immune cells of the endangered Tasmanian devil. Developmental and Comparative Immunology, 2015, 53, 123-133.	1.0	19
47	Immunology of a Transmissible Cancer Spreading among Tasmanian Devils. Journal of Immunology, 2015, 195, 23-29.	0.4	26
48	Identification of dendritic cells, B cell and T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infiltration into devil facial tumors. Anatomical Record, 2014, 297, 925-938.	0.8	35
49	Mouse Model of Devil Facial Tumour Disease Establishes That an Effective Immune Response Can be Generated Against the Cancer Cells. Frontiers in Immunology, 2014, 5, 251.	2.2	15
50	Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5103-5108.	3.3	191
51	Ultraviolet Radiation Effects on the Proteome of Skin Cells. Advances in Experimental Medicine and Biology, 2013, 990, 111-119.	0.8	21
52	Dietary vitamin D alters the response of the skin to UVB-irradiation depending on the genetic background of the mice. Photochemical and Photobiological Sciences, 2013, 12, 536-545.	1.6	14
53	Genome Sequencing and Analysis of the Tasmanian Devil and Its Transmissible Cancer. Cell, 2012, 148, 780-791.	13.5	300
54	Reduced Effect of Tasmanian Devil Facial Tumor Disease at the Disease Front. Conservation Biology, 2012, 26, 124-134.	2.4	69

#	Article	IF	Citations
55	UV-induced immunosuppression and the efficacy of vaccination. Photochemical and Photobiological Sciences, 2011, 10, 1267-1274.	1.6	35
56	Allorecognition in the Tasmanian Devil (Sarcophilus harrisii), an Endangered Marsupial Species with Limited Genetic Diversity. PLoS ONE, 2011, 6, e22402.	1.1	62
57	Novel application of a fish gill cell line assay to assess ichthyotoxicity of harmful marine microalgae. Harmful Algae, 2011, 10, 366-373.	2.2	50
58	Genetic diversity and population structure of the endangered marsupial <i>Sarcophilus harrisii</i> (Tasmanian devil). Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12348-12353.	3.3	189
59	A Murine Xenograft Model for a Transmissible Cancer in Tasmanian Devils. Veterinary Pathology, 2011, 48, 475-481.	0.8	25
60	Neonatal exposure to UVR alters skin immune system development, and suppresses immunity in adulthood. Immunology and Cell Biology, 2011, 89, 767-776.	1.0	13
61	Natural Killer Cell Mediated Cytotoxic Responses in the Tasmanian Devil. PLoS ONE, 2011, 6, e24475.	1.1	44
62	The Tasmanian Devil Transcriptome Reveals Schwann Cell Origins of a Clonally Transmissible Cancer. Science, 2010, 327, 84-87.	6.0	222
63	The two faces of metallothionein in carcinogenesis: photoprotection against UVR-induced cancer and promotion of tumour survival. Photochemical and Photobiological Sciences, 2010, 9, 586-596.	1.6	26
64	Vitamin D3 deficiency enhances contact hypersensitivity in male but not in female mice. Cellular Immunology, 2009, 255, 33-40.	1.4	15
65	A Histological and Immunohistochemical Analysis of Lymphoid Tissues of the Tasmanian Devil. Anatomical Record, 2009, 292, 611-620.	0.8	25
66	A Histological and Immunohistochemical Analysis of Lymphoid Tissues of the Tasmanian Devil. Anatomical Record, 2009, 292, spc1-spc1.	0.8	0
67	The humoral immune response of the Tasmanian devil (Sarcophilus harrisii) against horse red blood cells. Veterinary Immunology and Immunopathology, 2009, 130, 135-137.	0.5	24
68	Solar simulated ultraviolet radiation damages murine neonatal skin and alters Langerhans cell development, but does not induce inflammation. Photochemical and Photobiological Sciences, 2009, 8, 881-886.	1.6	2
69	Effect of UV Radiation on the Neonatal Skin Immune Systemâ€” Implications for Melanoma^{â€}. Photochemistry and Photobiology, 2008, 84, 47-54.	1.3	27
70	What's new in photoimmunology?. Photodermatology Photoimmunology and Photomedicine, 2008, 24, 334-336.	0.7	0
71	Mitogenâ€induced responses in lymphocytes from platypus, the Tasmanian devil and the eastern barred bandicoot. Australian Veterinary Journal, 2008, 86, 408-413.	0.5	8
72	Comment on "Hypothesisâ€"Ultraviolet-B Irradiance and Vitamin D Reduce the Risk of Viral Infections and thus their Sequelae, Including Autoimmune Diseases and some Cancers" by W.B. Grant, Photochem. Photobiol. (2007). Photochemistry and Photobiology, 2008, 84, 802-805.	1.3	0

#	Article	IF	Citations
73	Assessment of cellular immune responses of healthy and diseased Tasmanian devils (Sarcophilus) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.0	45
74	Transmission of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened carnivorous marsupial. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16221-16226.	3.3	246
75	Immune protection against photocarcinogenesis. Expert Review of Dermatology, 2007, 2, 543-547.	0.3	0
76	Proteomics identifies enhanced expression of stefin A in neonatal murine skin compared with adults: functional implications. British Journal of Dermatology, 2007, 156, 1156-1162.	1.4	24
77	What's new in photoimmunology?. Photodermatology Photoimmunology and Photomedicine, 2007, 23, 148-151.	0.7	0
78	The effect of season on cytokine expression in multiple sclerosis and healthy subjects. Journal of Neuroimmunology, 2007, 188, 181-186.	1.1	22
79	The Immune Response of the Tasmanian Devil (Sarcophilus harrisii) and Devil Facial Tumour Disease. EcoHealth, 2007, 4, 338-345.	0.9	66
80	Neonatal exposure to UVâ€B radiation leads to a large reduction in Langerhans cell density, but by maturity, there is an enhanced ability of dendritic cells to stimulate T cells. Immunology and Cell Biology, 2006, 84, 259-266.	1.0	7
81	Decrease in Langerhans Cells and Increase in Lymph Node Dendritic Cells Following Chronic Exposure of Mice to Suberythemal Doses of Solar Simulated Radiation. Photochemistry and Photobiology, 2005, 81, 1168.	1.3	22
82	What's new in photoimmunology?. Photodermatology Photoimmunology and Photomedicine, 2005, 21, 267-269.	0.7	0
83	An influx of macrophages is the predominant local immune response in ovine pulmonary adenocarcinoma. Veterinary Immunology and Immunopathology, 2005, 106, 285-294.	0.5	26
84	The skin immune system and the challenge of tumour immunosurveillance. European Journal of Dermatology, 2005, 15, 63-9.	0.3	38
85	In vitro testing to diagnose venom allergy and monitor immunotherapy: a placebo-controlled, crossover trial. Clinical and Experimental Allergy, 2004, 34, 792-800.	1.4	23
86	The Skin Immune System and Tumor Immunosurveillance. , 2004, , 475-494.		1
87	Antibody response to sheep red blood cells in platypus and echidna. Comparative Biochemistry and Physiology Part A, Molecular & Integrative Physiology, 2003, 136, 957-963.	0.8	11
88	Impaired CD40-signalling in Langerhansâ€™ cells from murine neonatal draining lymph nodes: implications for neonatally induced cutaneous tolerance. Clinical and Experimental Immunology, 2003, 132, 201-208.	1.1	19
89	DEC-205lo Langerinlo neonatal Langerhans' cells preferentially utilize a wortmannin-sensitive, fluid-phase pathway to internalize exogenous antigen. Immunology, 2003, 110, 466-473.	2.0	13
90	Mitochondrial cytochrome c release precedes transmembrane depolarisation and caspase-3 activation during ceramide-induced apoptosis of Jurkat T cells. Apoptosis: an International Journal on Programmed Cell Death, 2002, 7, 387-394.	2.2	41

#	Article	IF	Citations
91	Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein. British Journal of Haematology, 2001, 114, 177-184.	1.2	29
92	Acquisition of immune function during the development of the Langerhans cell network in neonatal mice. Immunology, 2001, 103, 61-69.	2.0	37
93	Cell cycle arrest of hematopoietic cell lines after treatment with ceramide is commonly associated with retinoblastoma activation. Cytometry, 2001, 43, 164-169.	1.8	8
94	Prevention of Autoimmunity by Induction of Cutaneous Tolerance. Cellular Immunology, 2001, 207, 1-5.	1.4	7
95	Carcinogen-modified dendritic cells induce immunosuppression by incomplete T-cell activation resulting from impaired antigen uptake and reduced CD86 expression. Immunology, 2000, 99, 16-22.	2.0	19
96	Induction of Peripheral Tolerance in Neonatally Thymectomized Mice by Immunization through Chemical Carcinogen-Altered Skin. Cellular Immunology, 1998, 189, 99-106.	1.4	1
97	P-glycoprotein mediated multidrug resistance and its implications for pathology. Pathology, 1997, 29, 122-130.	0.3	10
98	Chemical carcinogens and antigens contribute to cutaneous tumor promotion by depleting epidermal Langerhans cells. Carcinogenesis, 1997, 18, 1277-1279.	1.3	19
99	Down-regulation of an established immune response via chemical carcinogen or UVB-altered skin. Immunology and Cell Biology, 1997, 75, 238-244.	1.0	3
100	Failure of Carcinogen-Altered Dendritic Cells to Initiate T Cell Proliferation Is Associated with Reduced IL-1Î² Secretion. Cellular Immunology, 1997, 178, 17-23.	1.4	5
101	Chemical carcinogens and antigens induce immune suppression via Langerhans' cell depletion. Immunology, 1996, 88, 134-139.	2.0	29
102	Processing of complex antigens and simple hapten-like molecules by epidermal Langerhans cells. Journal of Leukocyte Biology, 1995, 57, 891-896.	1.5	5
103	Abrogation of Afferent Lymph Dendritic Cell Function after Cutaneously Applied Chemical Carcinogens. Cellular Immunology, 1995, 162, 80-88.	1.4	8
104	Defects in the Function of Dendritic Cells in Murine Retroviral Infection. Advances in Experimental Medicine and Biology, 1995, 378, 469-472.	0.8	6
105	Dendritic Cells Migrating from Carcinogen-Treated Skin Have Reduced Antigen-Presenting Function. Advances in Experimental Medicine and Biology, 1995, 378, 237-241.	0.8	4
106	Dendritic Cells, Apoptosis and Murine Retrovirus. Advances in Experimental Medicine and Biology, 1995, 378, 493-496.	0.8	0
107	Depletion of Langerhans Cells Following Carcinogen Treatment is Partly Due to Antigenicity. Advances in Experimental Medicine and Biology, 1993, 329, 623-627.	0.8	6